export type AntiarrhythmicClass = "Ia" | "Ib" | "Ic" | "II" | "III" | "IV";

export interface MedicationEntry {
  id: string;
  name: string;
  aliases: string[];
  drugClass: string;
  mechanism: string;
  indications: string[];
  adverseEffects: string[];
  boardsPearls: string[];
  antiarrhythmicClass?: AntiarrhythmicClass;
}

export const MEDICATIONS: MedicationEntry[] = [
  {
    id: "digoxin",
    name: "Digoxin",
    aliases: ["digoxin", "lanoxin"],
    drugClass: "Cardiac glycoside",
    mechanism:
      "Inhibits Na⁺/K⁺-ATPase → ↑ intracellular Ca²⁺ → positive inotropy; ↑ vagal tone → slows AV conduction.",
    indications: [
      "Symptomatic HFrEF",
      "Rate control in atrial fibrillation (especially with heart failure)",
    ],
    adverseEffects: [
      "Nausea, vomiting, anorexia",
      "Visual disturbances (yellow-green halos, blurred vision)",
      "Arrhythmias (PVCs, bradycardia, AV block, ventricular tachycardia)",
      "Narrow therapeutic window / toxicity",
    ],
    boardsPearls: [
      "Hypokalemia, hypomagnesemia, hypercalcemia, and renal failure increase toxicity",
      "Amiodarone, verapamil, and quinidine increase digoxin levels",
      "Toxicity antidote: digoxin-specific Fab fragments (binds free digoxin)",
    ],
  },
  {
    id: "furosemide",
    name: "Furosemide",
    aliases: ["furosemide", "lasix"],
    drugClass: "Loop diuretic",
    mechanism:
      "Inhibits Na⁺/K⁺/2Cl⁻ cotransporter in the thick ascending limb of the loop of Henle → potent natriuresis and diuresis.",
    indications: [
      "Acute pulmonary edema / volume overload",
      "Heart failure",
      "Edema (renal, hepatic, or cardiac)",
      "Hypertension (adjunct)",
    ],
    adverseEffects: [
      "Hypokalemia, hypomagnesemia, metabolic alkalosis",
      "Ototoxicity (especially with aminoglycosides)",
      "Dehydration, hypotension",
      "Hyperuricemia / gout",
    ],
    boardsPearls: [
      "Sulfonamide allergy: cross-reactivity possible but often still used cautiously",
      "Low ceiling effect compared with thiazides for HTN monotherapy",
      "Hypokalemia increases digoxin toxicity",
    ],
  },
  {
    id: "lisinopril",
    name: "Lisinopril",
    aliases: ["lisinopril"],
    drugClass: "ACE inhibitor",
    mechanism:
      "Blocks angiotensin-converting enzyme → ↓ angiotensin II and ↓ aldosterone → vasodilation, ↓ afterload, ↓ preload.",
    indications: [
      "Hypertension",
      "Heart failure (↓ mortality)",
      "Post-MI LV dysfunction",
      "Diabetic nephropathy",
    ],
    adverseEffects: [
      "Dry cough (bradykinin accumulation)",
      "Hyperkalemia",
      "Angioedema",
      "Teratogenic — contraindicated in pregnancy",
      "↑ creatinine / bilateral RAS can precipitate renal failure",
    ],
    boardsPearls: [
      "Contraindicated in pregnancy",
      "Avoid with bilateral renal artery stenosis",
      "Dry cough from bradykinin accumulation — ARBs do not inhibit kininase II",
    ],
  },
  {
    id: "enalapril",
    name: "Enalapril",
    aliases: ["enalapril"],
    drugClass: "ACE inhibitor",
    mechanism:
      "Prodrug converted to enalaprilat; inhibits ACE → ↓ angiotensin II and aldosterone → vasodilation and afterload reduction.",
    indications: [
      "Hypertension",
      "Heart failure",
      "Asymptomatic LV dysfunction",
    ],
    adverseEffects: [
      "Dry cough, hyperkalemia, angioedema",
      "Teratogenic — contraindicated in pregnancy",
      "Hypotension (first-dose effect)",
    ],
    boardsPearls: [
      "Same class pearls as other ACE inhibitors",
      "Prodrug requiring hepatic conversion (consider in liver disease)",
    ],
  },
  {
    id: "ace-inhibitors",
    name: "ACE inhibitors",
    aliases: [
      "ace inhibitors",
      "ace inhibitor",
      "acei",
      "ace-i",
      "angiotensin-converting enzyme inhibitors",
      "angiotensin converting enzyme inhibitors",
    ],
    drugClass: "Drug class",
    mechanism:
      "Block angiotensin-converting enzyme (kininase II) → ↓ angiotensin II and aldosterone → vasodilation, ↓ afterload, ↓ preload; ↑ bradykinin (cough, angioedema).",
    indications: [
      "Hypertension",
      "Heart failure (↓ mortality in HFrEF)",
      "Post-MI LV dysfunction",
      "Diabetic nephropathy / proteinuric CKD",
    ],
    adverseEffects: [
      "Dry cough (bradykinin)",
      "Hyperkalemia",
      "Angioedema",
      "Teratogenic — contraindicated in pregnancy",
      "↑ creatinine; bilateral renal artery stenosis → acute renal failure",
    ],
    boardsPearls: [
      "Examples: lisinopril, enalapril, captopril, ramipril",
      "Mortality benefit in HFrEF — cornerstone with β-blocker and MRA",
      "Contraindicated in pregnancy and bilateral renal artery stenosis",
      "Dry cough → switch to ARB (no kininase II inhibition)",
    ],
  },
  {
    id: "beta-blockers",
    name: "Beta blockers",
    aliases: [
      "beta blockers",
      "beta-blockers",
      "beta blocker",
      "beta-blocker",
      "β-blockers",
      "β blockers",
      "β-blocker",
      "bb",
    ],
    drugClass: "Drug class",
    mechanism:
      "Antagonize β-adrenergic receptors → ↓ heart rate, contractility, and renin release; reduce myocardial O₂ demand.",
    indications: [
      "Hypertension",
      "Angina",
      "Heart failure (chronic, stabilized HFrEF)",
      "Post-MI",
      "Rate control in atrial fibrillation",
      "Migraine prophylaxis, essential tremor (propranolol)",
    ],
    adverseEffects: [
      "Bradycardia, AV block, acute HF exacerbation",
      "Bronchospasm (especially nonselective agents)",
      "Masks hypoglycemia symptoms",
      "Fatigue, depression, impotence",
      "Rebound tachycardia/ischemia if withdrawn abruptly",
    ],
    boardsPearls: [
      "Examples: metoprolol, atenolol (β1-selective); propranolol (nonselective)",
      "Contraindicated in acute decompensated HF",
      "β1-selective preferred in asthma but still use caution",
      "Rate control in AF; avoid in WPW + AF (use procainamide instead)",
    ],
  },
  {
    id: "calcium-channel-blockers",
    name: "Calcium channel blockers",
    aliases: [
      "calcium channel blockers",
      "calcium channel blocker",
      "calcium-channel blockers",
      "calcium-channel blocker",
      "ccb",
      "ccbs",
    ],
    drugClass: "Drug class",
    mechanism:
      "Block L-type voltage-gated Ca²⁺ channels → reduced Ca²⁺ influx; effects depend on subclass (cardiac vs vascular selectivity).",
    indications: [
      "Hypertension",
      "Angina (stable and vasospastic)",
      "Rate control in AF/flutter (nondihydropyridines only)",
      "Supraventricular tachycardia (nondihydropyridines)",
    ],
    adverseEffects: [
      "Peripheral edema (especially dihydropyridines)",
      "Bradycardia and AV block (nondihydropyridines)",
      "Constipation (verapamil)",
      "Gingival hyperplasia",
      "Hypotension, reflex tachycardia (dihydropyridines)",
    ],
    boardsPearls: [
      "Two subclasses: dihydropyridines (vascular) vs nondihydropyridines (cardiac/AV nodal)",
      "Dihydropyridines: amlodipine, nifedipine — HTN/angina, not AV nodal rate control",
      "Nondihydropyridines: diltiazem, verapamil — rate control, AV nodal effects",
      "Avoid nondihydropyridine + β-blocker + digoxin combination (AV nodal depression)",
    ],
  },
  {
    id: "nondihydropyridine-calcium-channel-blockers",
    name: "Nondihydropyridine calcium channel blockers",
    aliases: [
      "nondihydropyridine calcium channel blockers",
      "nondihydropyridine calcium channel blocker",
      "nondihydropyridine ccb",
      "nondihydropyridine ccbs",
      "nondihydropyridine",
      "non-dihydropyridine calcium channel blocker",
      "non dihydropyridine ccb",
    ],
    drugClass: "Drug subclass",
    mechanism:
      "Block L-type Ca²⁺ channels in cardiac SA/AV node and vascular smooth muscle → ↓ AV nodal conduction and contractility; moderate vasodilation.",
    indications: [
      "Rate control in atrial fibrillation/flutter",
      "Supraventricular tachycardia",
      "Hypertension and angina",
    ],
    adverseEffects: [
      "Bradycardia, AV block, heart failure exacerbation",
      "Constipation (verapamil > diltiazem)",
      "Peripheral edema, hypotension",
      "Gingival hyperplasia (verapamil)",
    ],
    boardsPearls: [
      "Examples: diltiazem, verapamil (Class IV antiarrhythmics)",
      "Cardiac/AV nodal effects dominate — used for AF rate control",
      "Contraindicated in WPW + AF (shortens accessory pathway refractory period)",
      "Additive AV nodal depression with β-blockers and digoxin",
    ],
  },
  {
    id: "dihydropyridine-calcium-channel-blockers",
    name: "Dihydropyridine calcium channel blockers",
    aliases: [
      "dihydropyridine calcium channel blockers",
      "dihydropyridine calcium channel blocker",
      "dihydropyridine ccb",
      "dihydropyridine ccbs",
      "dihydropyridine",
      "dhp ccb",
    ],
    drugClass: "Drug subclass",
    mechanism:
      "Block L-type Ca²⁺ channels predominantly in vascular smooth muscle → arteriolar vasodilation with minimal direct SA/AV nodal depression.",
    indications: [
      "Hypertension",
      "Chronic stable angina",
      "Vasospastic (Prinzmetal) angina",
      "Raynaud phenomenon",
    ],
    adverseEffects: [
      "Peripheral edema (arteriolar dilation → ↑ capillary hydrostatic pressure)",
      "Flushing, headache, dizziness",
      "Reflex tachycardia (more with short-acting nifedipine)",
      "Gingival hyperplasia (nifedipine)",
    ],
    boardsPearls: [
      "Examples: amlodipine, nifedipine, felodipine, nicardipine",
      "Vascular selectivity — not first-line for AF rate control",
      "Peripheral edema often not fixed by diuretics alone",
      "Safer to combine with β-blockers than nondihydropyridines (less AV nodal depression)",
    ],
  },
  {
    id: "metoprolol",
    name: "Metoprolol",
    aliases: ["metoprolol", "lopressor"],
    drugClass: "Beta-1 selective blocker",
    mechanism:
      "Antagonizes β1 receptors → ↓ heart rate, contractility, and renin release; reduces myocardial O₂ demand.",
    indications: [
      "Hypertension",
      "Angina",
      "Heart failure (chronic, stabilized)",
      "Post-MI",
      "Rate control in atrial fibrillation",
    ],
    adverseEffects: [
      "Bradycardia, AV block, heart failure exacerbation (acute decompensated HF)",
      "Bronchospasm (less than nonselective β-blockers)",
      "Fatigue, depression, impotence",
      "Masks hypoglycemia symptoms",
    ],
    boardsPearls: [
      "Contraindicated in acute decompensated HF (↓ contractility worsens pump failure)",
      "Avoid abrupt withdrawal → rebound tachycardia / ischemia",
      "β1-selective but still use caution in asthma",
    ],
  },
  {
    id: "atenolol",
    name: "Atenolol",
    aliases: ["atenolol", "tenormin"],
    drugClass: "Beta-1 selective blocker",
    mechanism:
      "Antagonizes β1 receptors → ↓ heart rate, contractility, and renin release; hydrophilic β-blocker with minimal CNS penetration.",
    indications: [
      "Hypertension",
      "Angina",
      "Post-MI",
      "Rate control in atrial fibrillation",
    ],
    adverseEffects: [
      "Bradycardia, AV block, heart failure exacerbation (acute decompensated HF)",
      "Bronchospasm (less than nonselective β-blockers)",
      "Fatigue, cold extremities",
      "Masks hypoglycemia symptoms",
    ],
    boardsPearls: [
      "Hydrophilic β1-blocker — renally excreted; reduce dose in renal failure",
      "Less CNS side effects than lipophilic agents (propranolol, metoprolol)",
      "β1-selective but still use caution in asthma/COPD",
      "Avoid abrupt withdrawal → rebound tachycardia / ischemia",
    ],
  },
  {
    id: "amiodarone",
    name: "Amiodarone",
    aliases: ["amiodarone", "pacerone"],
    drugClass: "Class III antiarrhythmic (multichannel blocker)",
    antiarrhythmicClass: "III",
    mechanism:
      "Blocks K⁺, Na⁺, and Ca²⁺ channels and has noncompetitive β-blockade → prolongs action potential and refractory period.",
    indications: [
      "Ventricular arrhythmias",
      "Atrial fibrillation/flutter (rate and rhythm control)",
      "Refractory supraventricular tachycardias",
    ],
    adverseEffects: [
      "Pulmonary fibrosis / pneumonitis",
      "Hepatotoxicity, corneal microdeposits, photosensitivity",
      "Hypo- or hyperthyroidism",
      "QT prolongation, bradycardia, heart block",
      "Blue-gray skin discoloration (long-term)",
    ],
    boardsPearls: [
      "Many drug interactions via CYP inhibition; increases digoxin levels",
      "Contains iodine → thyroid dysfunction",
      "Long-term toxicities: pulmonary fibrosis, hepatotoxicity, corneal deposits, thyroid dysfunction",
    ],
  },
  {
    id: "adenosine",
    name: "Adenosine",
    aliases: ["adenosine", "adenocard"],
    drugClass: "Purine nucleoside / antiarrhythmic",
    mechanism:
      "Activates A1 receptors → ↑ K⁺ efflux → hyperpolarization and transient AV nodal block; very short half-life (seconds).",
    indications: [
      "Paroxysmal supraventricular tachycardia (AV nodal block)",
      "Diagnostic maneuver in wide-complex tachycardia (transient AV block)",
    ],
    adverseEffects: [
      "Transient flushing, chest discomfort, dyspnea",
      "Brief asystole or bradycardia (expected)",
      "Bronchospasm (use caution in asthma/COPD)",
    ],
    boardsPearls: [
      "Half-life ~10 seconds — terminated by RBC/endothelial uptake",
      "Ineffective orally or as slow infusion (degraded before reaching AV node)",
      "Methylxanthines (caffeine, theophylline) antagonize effect",
      "Pediatrics: same mechanism in SVT; blocked by methylxanthines",
    ],
  },
  {
    id: "diltiazem",
    name: "Diltiazem",
    aliases: ["diltiazem", "cardizem"],
    drugClass: "Class IV antiarrhythmic / nondihydropyridine calcium channel blocker",
    antiarrhythmicClass: "IV",
    mechanism:
      "Blocks L-type Ca²⁺ channels in cardiac SA/AV node and vascular smooth muscle → ↓ AV nodal conduction and contractility; peripheral vasodilation.",
    indications: [
      "Rate control in atrial fibrillation/flutter",
      "Supraventricular tachycardia",
      "Hypertension and angina",
    ],
    adverseEffects: [
      "Bradycardia, AV block, heart failure exacerbation",
      "Peripheral edema, constipation",
      "Hypotension",
      "Gingival hyperplasia (less common than verapamil)",
    ],
    boardsPearls: [
      "Nondihydropyridine CCB — cardiac effects dominate (vs amlodipine/nifedipine)",
      "Avoid with β-blockers or digoxin → additive AV nodal depression",
      "Contraindicated in WPW with AF (shortens refractory period in accessory pathway → ↑ ventricular rate)",
      "Pediatrics: same AV nodal effects; used cautiously for SVT rate control",
    ],
  },
  {
    id: "amlodipine",
    name: "Amlodipine",
    aliases: ["amlodipine", "norvasc"],
    drugClass: "Dihydropyridine calcium channel blocker",
    mechanism:
      "Blocks L-type Ca²⁺ channels in vascular smooth muscle → arteriolar vasodilation with minimal direct cardiac conduction effects (peripheral > cardiac selectivity).",
    indications: [
      "Hypertension",
      "Chronic stable angina",
      "Vasospastic (Prinzmetal) angina",
      "Coronary artery disease",
    ],
    adverseEffects: [
      "Peripheral edema (arteriolar dilation → capillary hydrostatic pressure)",
      "Flushing, headache, dizziness",
      "Reflex tachycardia (less than immediate-release nifedipine)",
      "Gingival hyperplasia (less common than nifedipine)",
    ],
    boardsPearls: [
      "Dihydropyridine CCB — vascular effects dominate (vs diltiazem/verapamil)",
      "Peripheral edema is common — not relieved by diuretics alone (arteriolar dilation mechanism)",
      "Does not significantly depress AV nodal conduction — safer with β-blockers than nondihydropyridines",
      "Long half-life → once-daily dosing",
    ],
  },
  {
    id: "nifedipine",
    name: "Nifedipine",
    aliases: ["nifedipine", "procardia", "adalat"],
    drugClass: "Dihydropyridine calcium channel blocker",
    mechanism:
      "Blocks L-type Ca²⁺ channels in vascular smooth muscle → potent arteriolar vasodilation; immediate-release formulation causes rapid hypotension and reflex tachycardia.",
    indications: [
      "Hypertension (extended-release preferred)",
      "Chronic stable angina",
      "Vasospastic (Prinzmetal) angina",
      "Raynaud phenomenon",
      "Tocolysis (acute preterm labor — specific formulations)",
    ],
    adverseEffects: [
      "Reflex tachycardia (especially immediate-release)",
      "Hypotension, flushing, headache",
      "Peripheral edema",
      "Gingival hyperplasia (classic association)",
    ],
    boardsPearls: [
      "Immediate-release nifedipine: avoid for HTN emergencies — unpredictable hypotension and reflex tachycardia",
      "Extended-release preferred for chronic HTN/angina",
      "Dihydropyridine CCB — not used for AF rate control (unlike diltiazem/verapamil)",
      "Gingival hyperplasia more common than with amlodipine",
    ],
  },
  {
    id: "procainamide",
    name: "Procainamide",
    aliases: ["procainamide", "pronestyl"],
    drugClass: "Class Ia antiarrhythmic",
    antiarrhythmicClass: "Ia",
    mechanism:
      "Blocks fast Na⁺ channels → moderate Na⁺ channel blockade, ↑ action potential duration and effective refractory period; active metabolite N-acetylprocainamide (NAPA) prolongs repolarization.",
    indications: [
      "Ventricular arrhythmias",
      "Supraventricular arrhythmias (atrial fibrillation/flutter, WPW)",
    ],
    adverseEffects: [
      "Drug-induced lupus (positive ANA, anti-histone antibodies)",
      "Hypotension (especially with IV loading)",
      "QT prolongation / torsades de pointes",
      "Agranulocytosis (rare)",
      "Negative inotropy",
    ],
    boardsPearls: [
      "Class Ia: moderate Na⁺ channel block + ↑ APD (quinidine-like)",
      "Classic drug-induced lupus — slow acetylators at higher risk; reversible on discontinuation",
      "NAPA metabolite has Class III–like repolarization effects",
      "Pediatrics: rarely used; lupus risk and hemodynamic effects limit routine use",
    ],
  },
  {
    id: "quinidine",
    name: "Quinidine",
    aliases: ["quinidine", "quinidex", "quinora"],
    drugClass: "Class Ia antiarrhythmic",
    antiarrhythmicClass: "Ia",
    mechanism:
      "Blocks fast Na⁺ channels and K⁺ channels → moderate Na⁺ blockade with ↑ action potential duration and effective refractory period; also α-adrenergic blockade.",
    indications: [
      "Atrial fibrillation/flutter (rhythm control)",
      "Ventricular arrhythmias",
      "Malaria (historical)",
    ],
    adverseEffects: [
      "Cinchonism (tinnitus, headache, nausea, blurred vision)",
      "QT prolongation / torsades de pointes",
      "Diarrhea (common — limits long-term use)",
      "Thrombocytopenia, hemolytic anemia",
      "Drug-induced lupus (less common than procainamide)",
    ],
    boardsPearls: [
      "Class Ia: moderate Na⁺ channel block + ↑ APD",
      "Increases digoxin levels — displaces digoxin from tissue binding and ↓ renal clearance",
      "Contraindicated in myasthenia gravis — worsens neuromuscular blockade",
      "Pediatrics: rarely first-line; cinchonism and GI intolerance limit use",
    ],
  },
  {
    id: "disopyramide",
    name: "Disopyramide",
    aliases: ["disopyramide", "norpace"],
    drugClass: "Class Ia antiarrhythmic",
    antiarrhythmicClass: "Ia",
    mechanism:
      "Blocks fast Na⁺ channels and has antimuscarinic activity → ↑ action potential duration and effective refractory period; negative inotropy.",
    indications: [
      "Ventricular arrhythmias",
      "Supraventricular arrhythmias (selected cases)",
    ],
    adverseEffects: [
      "Anticholinergic effects (dry mouth, urinary retention, constipation)",
      "Negative inotropy → heart failure exacerbation",
      "QT prolongation / torsades de pointes",
      "Hypoglycemia (especially in diabetics)",
    ],
    boardsPearls: [
      "Class Ia: moderate Na⁺ channel block + ↑ APD (quinidine-like)",
      "Strong anticholinergic and negative inotropic effects — avoid in HFrEF",
      "Use with caution in structural heart disease",
      "Pediatrics: rarely first-line; anticholinergic and inotropic effects limit use",
    ],
  },
  {
    id: "flecainide",
    name: "Flecainide",
    aliases: ["flecainide", "tambocor"],
    drugClass: "Class Ic antiarrhythmic",
    antiarrhythmicClass: "Ic",
    mechanism:
      "Strong block of fast Na⁺ channels → markedly slows conduction (↓ Vmax) with minimal effect on action potential duration.",
    indications: [
      "Supraventricular arrhythmias (including atrial fibrillation/flutter in structurally normal hearts)",
      "Life-threatening ventricular arrhythmias (selected patients without structural heart disease)",
    ],
    adverseEffects: [
      "Proarrhythmia (new or worsened ventricular arrhythmias)",
      "Bradycardia, heart block",
      "Dizziness, visual disturbances",
      "Negative inotropy",
    ],
    boardsPearls: [
      "Class Ic: strong Na⁺ block, minimal APD change — \"can organize\" AF into slow atrial flutter with 1:1 conduction",
      "Contraindicated in structural heart disease (post-MI, CAD, HFrEF) — CAST trial ↑ mortality",
      "Useful for rhythm control in lone AF with normal heart",
      "Pediatrics: reserved for refractory SVT in structurally normal hearts under specialist care",
    ],
  },
  {
    id: "propafenone",
    name: "Propafenone",
    aliases: ["propafenone", "rythmol"],
    drugClass: "Class Ic antiarrhythmic",
    antiarrhythmicClass: "Ic",
    mechanism:
      "Strong block of fast Na⁺ channels → markedly slows conduction (↓ Vmax) with minimal effect on action potential duration; weak β-adrenergic blockade.",
    indications: [
      "Supraventricular arrhythmias (including atrial fibrillation/flutter in structurally normal hearts)",
      "Ventricular arrhythmias (selected patients without structural heart disease)",
    ],
    adverseEffects: [
      "Proarrhythmia (new or worsened ventricular arrhythmias)",
      "Bradycardia, heart block",
      "Metallic taste, dizziness, nausea",
      "Negative inotropy",
      "Bronchospasm (weak β-blockade)",
    ],
    boardsPearls: [
      "Class Ic: strong Na⁺ block, minimal APD change — like flecainide",
      "Contraindicated in structural heart disease (CAD, post-MI, HFrEF) — proarrhythmia risk",
      "Intrinsic β-blocking activity — additive bradycardia with other nodal depressants",
      "Pediatrics: reserved for refractory SVT in structurally normal hearts under specialist care",
    ],
  },
  {
    id: "lidocaine",
    name: "Lidocaine",
    aliases: ["lidocaine", "xylocaine"],
    drugClass: "Class Ib antiarrhythmic / local anesthetic",
    antiarrhythmicClass: "Ib",
    mechanism:
      "Blocks fast Na⁺ channels preferentially in depolarized or ischemic tissue → shortens action potential duration; minimal effect on normal tissue.",
    indications: [
      "Ventricular arrhythmias (especially post-MI)",
      "Local/regional anesthesia",
    ],
    adverseEffects: [
      "CNS toxicity (perioral numbness, seizures, confusion)",
      "Cardiovascular depression at high doses",
      "Drowsiness, tinnitus",
    ],
    boardsPearls: [
      "Class Ib: preferentially binds inactivated Na⁺ channels in ischemic myocardium",
      "IV antiarrhythmic use largely replaced by amiodarone, but classic post-MI VT/VF drug",
      "CNS toxicity before cardiovascular collapse — perioral numbness is early warning",
      "Pediatrics: same ischemia-selective binding; toxicity risk ↑ with liver dysfunction",
    ],
  },
  {
    id: "mexiletine",
    name: "Mexiletine",
    aliases: ["mexiletine", "mexitil"],
    drugClass: "Class Ib antiarrhythmic",
    antiarrhythmicClass: "Ib",
    mechanism:
      "Blocks fast Na⁺ channels preferentially in depolarized or ischemic tissue → shortens action potential duration; oral analog of lidocaine.",
    indications: [
      "Ventricular arrhythmias (chronic oral therapy)",
      "Neuropathic pain (off-label)",
    ],
    adverseEffects: [
      "GI upset (nausea, vomiting)",
      "CNS effects (tremor, ataxia, dizziness, confusion)",
      "Bradycardia, heart block (less common)",
      "Hepatotoxicity (rare)",
    ],
    boardsPearls: [
      "Class Ib: preferentially binds inactivated Na⁺ channels — lidocaine-like but oral",
      "Useful for chronic oral suppression of ventricular arrhythmias when IV lidocaine is not practical",
      "CNS toxicity before cardiovascular collapse — dose-reduce in liver disease",
      "Pediatrics: rarely used; CNS and GI side effects limit routine use",
    ],
  },
  {
    id: "propranolol",
    name: "Propranolol",
    aliases: ["propranolol", "inderal"],
    drugClass: "Nonselective β-blocker (Class II antiarrhythmic)",
    antiarrhythmicClass: "II",
    mechanism:
      "Antagonizes β1 and β2 receptors → ↓ heart rate, contractility, and AV nodal conduction; ↓ renin release.",
    indications: [
      "Hypertension, angina, migraine prophylaxis",
      "Rate control in atrial fibrillation",
      "Thyrotoxicosis / thyroid storm",
      "Infantile hemangioma",
      "Essential tremor, performance anxiety",
    ],
    adverseEffects: [
      "Bronchospasm (β2 blockade)",
      "Bradycardia, AV block, heart failure exacerbation",
      "Masks hypoglycemia symptoms",
      "Fatigue, vivid dreams, impotence",
    ],
    boardsPearls: [
      "Nonselective β-blocker — avoid in asthma/COPD (unlike metoprolol/atenolol)",
      "Class II antiarrhythmic: ↓ cAMP → ↓ Ca²⁺ influx in nodal tissue",
      "Treats thyrotoxic symptoms (↓ peripheral T4→T3 conversion)",
      "Pediatrics: first-line for infantile hemangioma; bronchospasm risk limits use in reactive airway disease",
    ],
  },
  {
    id: "alteplase",
    name: "Alteplase",
    aliases: ["alteplase", "tpa", "t-pa", "activase"],
    drugClass: "Thrombolytic (tissue plasminogen activator)",
    mechanism:
      "Converts plasminogen to plasmin → fibrinolysis and clot dissolution.",
    indications: [
      "Acute ischemic stroke",
      "STEMI (fibrinolysis)",
      "Massive pulmonary embolism with hemodynamic instability",
    ],
    adverseEffects: [
      "Intracranial hemorrhage",
      "Systemic bleeding",
      "Reperfusion arrhythmias",
    ],
    boardsPearls: [
      "Contraindications: recent stroke/surgery, active bleeding, uncontrolled HTN",
      "Converts plasminogen → plasmin; major risk is intracranial hemorrhage",
      "Tenecteplase: modified tPA with longer half-life (fibrin-specific)",
    ],
  },
  {
    id: "atropine",
    name: "Atropine",
    aliases: ["atropine"],
    drugClass: "Antimuscarinic (anticholinergic)",
    mechanism:
      "Competitive muscarinic (M) receptor antagonist → blocks vagal effects on SA/AV node and smooth muscle.",
    indications: [
      "Symptomatic bradycardia",
      "Organophosphate/carbamate poisoning (with pralidoxime)",
      "Cycloplegia / mydriasis (ophthalmic)",
    ],
    adverseEffects: [
      "Tachycardia, dry mouth, urinary retention",
      "Confusion, hyperthermia (especially elderly)",
      "Mydriasis, acute angle-closure glaucoma risk",
      "Paradoxical bradycardia at low doses",
    ],
    boardsPearls: [
      "Muscarinic antagonist → ↑ HR via M2 blockade on SA/AV node",
      "Not effective for high-degree (type II second-degree or third-degree) AV block",
      "Organophosphate poisoning → atropine + pralidoxime (reactivates acetylcholinesterase)",
      "Pediatrics: bradycardia in infants often from hypoxia — address airway first",
    ],
  },
  {
    id: "morphine",
    name: "Morphine",
    aliases: ["morphine", "ms contin"],
    drugClass: "Opioid agonist (μ-receptor)",
    mechanism:
      "Agonist at μ-opioid receptors (and κ, δ) → ↑ analgesia, sedation, and respiratory depression; ↓ sympathetic outflow.",
    indications: [
      "Moderate to severe pain (acute and chronic)",
      "Acute pulmonary edema (reduces preload and sympathetic surge)",
      "Acute coronary syndrome / MI-related chest pain",
    ],
    adverseEffects: [
      "Respiratory depression",
      "Nausea, vomiting, constipation",
      "Miosis, sedation, urinary retention",
      "Hypotension and bradycardia",
      "Physical dependence and withdrawal",
    ],
    boardsPearls: [
      "Reversed by naloxone; shorter naloxone half-life → risk of renarcotization",
      "Avoid in severe asthma, COPD, or undiagnosed head injury (↑ CO₂ retention / ↑ ICP)",
      "Active metabolite morphine-6-glucuronide accumulates in renal failure → prolonged toxicity",
      "Pediatrics: respiratory depression is leading toxicity; same μ-receptor mechanism",
    ],
  },
  {
    id: "naloxone",
    name: "Naloxone",
    aliases: ["naloxone", "narcan"],
    drugClass: "Opioid antagonist",
    mechanism:
      "Competitive antagonist at μ, κ, and δ opioid receptors → reverses opioid-induced CNS and respiratory depression.",
    indications: [
      "Opioid overdose (respiratory depression, altered mental status)",
    ],
    adverseEffects: [
      "Acute opioid withdrawal (agitation, vomiting, diarrhea, tachycardia)",
      "Pulmonary edema (rare)",
      "Recurrent depression as naloxone wears off (shorter half-life than many opioids)",
    ],
    boardsPearls: [
      "Pinpoint pupils + ↓ respirations → opioid toxicity; competitive μ-receptor antagonist",
      "Shorter half-life than most opioids → renarcotization risk as naloxone wears off",
      "Precipitates acute withdrawal in opioid-dependent patients",
      "Pediatrics: same toxidrome; accidental ingestion or iatrogenic overdose",
    ],
  },
  {
    id: "physostigmine",
    name: "Physostigmine",
    aliases: ["physostigmine", "antilirium"],
    drugClass: "Reversible acetylcholinesterase inhibitor",
    mechanism:
      "Crosses blood-brain barrier; inhibits acetylcholinesterase → ↑ synaptic ACh at muscarinic and nicotinic sites.",
    indications: [
      "Anticholinergic (antimuscarinic) toxicity with CNS effects",
    ],
    adverseEffects: [
      "Bradycardia, salivation, bronchorrhea, seizures",
      "Cholinergic crisis if overdosed",
      "Contraindicated in TCA overdose (may worsen cardiac conduction)",
    ],
    boardsPearls: [
      "Antidote for pure anticholinergic toxidrome: hot as a hare, dry as a bone, mad as a hatter, blind as a bat",
      "Contraindicated in QRS widening / TCA ingestion — use sodium bicarbonate instead",
      "Atropine treats peripheral cholinergic excess; physostigmine treats central anticholinergic delirium",
      "Pediatrics: accidental diphenhydramine or scopolamine ingestion — same contraindications apply",
    ],
  },
  {
    id: "heparin",
    name: "Heparin",
    aliases: [
      "heparin",
      "unfractionated heparin",
      "ufh",
    ],
    drugClass: "Anticoagulant (indirect thrombin inhibitor)",
    mechanism:
      "Binds antithrombin III → markedly ↑ inhibition of factor Xa and thrombin (IIa).",
    indications: [
      "Acute venous thromboembolism",
      "Acute coronary syndromes",
      "Atrial fibrillation",
      "DIC (selected cases)",
    ],
    adverseEffects: [
      "Bleeding",
      "Heparin-induced thrombocytopenia (HIT)",
      "Osteoporosis (prolonged use)",
      "Hyperkalemia (suppressed aldosterone)",
    ],
    boardsPearls: [
      "Binds antithrombin III → potentiates inhibition of thrombin (IIa) and factor Xa",
      "HIT: immune-mediated anti-PF4 antibodies → thrombocytopenia + thrombosis",
      "Protamine sulfate reverses UFH (cationic protein binds acidic heparin)",
    ],
  },
  {
    id: "warfarin",
    name: "Warfarin",
    aliases: ["warfarin", "coumadin"],
    drugClass: "Vitamin K antagonist",
    mechanism:
      "Inhibits vitamin K epoxide reductase → impairs synthesis of factors II, VII, IX, X and proteins C & S.",
    indications: [
      "Atrial fibrillation (stroke prevention)",
      "Mechanical heart valves",
      "Venous thromboembolism treatment/prevention",
    ],
    adverseEffects: [
      "Bleeding",
      "Skin necrosis (protein C deficiency early on)",
      "Teratogenic — contraindicated in pregnancy",
    ],
    boardsPearls: [
      "Inhibits vitamin K epoxide reductase → ↓ factors II, VII, IX, X and protein C & S",
      "Narrow therapeutic window; vitamin K–rich foods and CYP2C9 inhibitors ↑ effect",
      "Skin necrosis early in therapy if congenital protein C deficiency",
      "Teratogenic — crosses placenta; fetal hemorrhage risk",
    ],
  },
  {
    id: "apixaban",
    name: "Apixaban",
    aliases: ["apixaban", "eliquis"],
    drugClass: "Direct factor Xa inhibitor (DOAC)",
    mechanism:
      "Directly inhibits factor Xa → ↓ thrombin generation without requiring antithrombin.",
    indications: [
      "Nonvalvular atrial fibrillation (stroke prevention)",
      "VTE treatment and prophylaxis",
    ],
    adverseEffects: [
      "Bleeding",
    ],
    boardsPearls: [
      "Direct factor Xa inhibitor — inhibits thrombin generation without antithrombin",
      "Contraindicated with mechanical heart valves (thrombosis risk)",
      "Renally cleared — accumulation risk with impaired kidney function",
    ],
  },
  {
    id: "rivaroxaban",
    name: "Rivaroxaban",
    aliases: ["rivaroxaban", "xarelto"],
    drugClass: "Direct factor Xa inhibitor (DOAC)",
    mechanism:
      "Directly inhibits factor Xa → ↓ thrombin generation without requiring antithrombin.",
    indications: [
      "Nonvalvular atrial fibrillation (stroke prevention)",
      "VTE treatment and prophylaxis (including post-orthopedic surgery)",
    ],
    adverseEffects: [
      "Bleeding",
      "GI upset",
    ],
    boardsPearls: [
      "Direct factor Xa inhibitor — once-daily dosing (food ↑ absorption)",
      "Contraindicated with mechanical heart valves",
      "Renally cleared — dose adjustment with impaired kidney function",
    ],
  },
  {
    id: "dabigatran",
    name: "Dabigatran",
    aliases: ["dabigatran", "pradaxa"],
    drugClass: "Direct thrombin inhibitor (DOAC)",
    mechanism:
      "Directly inhibits thrombin (factor IIa) → prevents fibrin formation.",
    indications: [
      "Nonvalvular atrial fibrillation (stroke prevention)",
      "VTE treatment",
    ],
    adverseEffects: [
      "Bleeding",
      "Dyspepsia",
    ],
    boardsPearls: [
      "Only oral direct thrombin inhibitor among DOACs",
      "Reversal agent: idarucizumab (Fab fragment)",
      "Contraindicated with mechanical heart valves",
    ],
  },
  {
    id: "lmwh",
    name: "Low-Molecular-Weight Heparin (LMWH)",
    aliases: [
      "lmwh",
      "low molecular weight heparin",
      "low-molecular-weight heparin",
      "low molecular weight heparins",
    ],
    drugClass: "Anticoagulant (indirect factor Xa inhibitor)",
    mechanism:
      "Short heparin chains bind antithrombin III → preferential inhibition of factor Xa over thrombin (higher anti-Xa:anti-IIa ratio than unfractionated heparin).",
    indications: [
      "VTE treatment and prophylaxis",
      "Acute coronary syndromes",
      "Bridging anticoagulation",
    ],
    adverseEffects: [
      "Bleeding",
      "Heparin-induced thrombocytopenia (less common than with UFH)",
      "Injection-site hematoma",
    ],
    boardsPearls: [
      "LMWH (e.g., enoxaparin, dalteparin) — mainly anti-Xa activity; subcutaneous, predictable PK",
      "Renally cleared — avoid or reduce dose if CrCl <30",
      "Protamine only partially reverses anti-Xa effect",
      "UFH inhibits Xa and IIa more equally; LMWH has less anti-IIa activity",
    ],
  },
  {
    id: "enoxaparin",
    name: "Enoxaparin",
    aliases: ["enoxaparin", "lovenox"],
    drugClass: "Low-molecular-weight heparin (LMWH)",
    mechanism:
      "Binds antithrombin III → preferentially inhibits factor Xa over thrombin (higher anti-Xa:anti-IIa ratio than UFH).",
    indications: [
      "VTE treatment and prophylaxis",
      "Acute coronary syndromes",
      "Bridging anticoagulation",
    ],
    adverseEffects: [
      "Bleeding",
      "Heparin-induced thrombocytopenia (HIT, less common than UFH)",
      "Injection-site hematoma",
    ],
    boardsPearls: [
      "LMWH — mainly anti-Xa activity; subcutaneous dosing, predictable PK (no routine monitoring)",
      "Renally cleared — avoid or reduce dose if CrCl <30",
      "Protamine partially reverses anti-Xa effect (less complete than for UFH)",
      "HIT still possible — switch to argatroban or fondaparinux if suspected",
    ],
  },
  {
    id: "fondaparinux",
    name: "Fondaparinux",
    aliases: ["fondaparinux", "arixtra"],
    drugClass: "Synthetic factor Xa inhibitor",
    mechanism:
      "Synthetic pentasaccharide that binds antithrombin III → selective factor Xa inhibition (no direct thrombin inhibition).",
    indications: [
      "VTE prophylaxis and treatment",
      "HIT (alternative anticoagulant when heparin contraindicated)",
    ],
    adverseEffects: [
      "Bleeding",
      "Injection-site reactions",
    ],
    boardsPearls: [
      "Synthetic pentasaccharide — selective anti-Xa without anti-IIa activity",
      "Safe in HIT (no PF4-heparin complex formation)",
      "Renally cleared — contraindicated if CrCl <30",
      "No protamine reversal — long half-life",
    ],
  },
  {
    id: "clopidogrel",
    name: "Clopidogrel",
    aliases: ["clopidogrel", "plavix"],
    drugClass: "P2Y12 ADP receptor antagonist (thienopyridine)",
    mechanism:
      "Irreversible P2Y12 ADP receptor blockade on platelets → ↓ GPIIb/IIIa activation and platelet aggregation.",
    indications: [
      "Acute coronary syndrome",
      "Post-PCI stent thrombosis prevention",
      "Secondary stroke prevention",
      "Peripheral arterial disease",
    ],
    adverseEffects: [
      "Bleeding",
      "Thrombotic thrombocytopenic purpura (rare)",
      "Rash, diarrhea",
    ],
    boardsPearls: [
      "Prodrug — requires CYP2C19 activation; poor metabolizers have ↓ efficacy",
      "Irreversible P2Y12 blockade — effect lasts platelet lifespan (~7–10 days)",
      "Combined with aspirin in ACS/PCI (dual antiplatelet therapy)",
      "Omeprazole may ↓ activation via CYP2C19 inhibition (clinical significance debated)",
    ],
  },
  {
    id: "ticagrelor",
    name: "Ticagrelor",
    aliases: ["ticagrelor", "brilinta"],
    drugClass: "P2Y12 ADP receptor antagonist (cyclopentyltriazolopyrimidine)",
    mechanism:
      "Reversible, noncompetitive P2Y12 ADP receptor blockade → ↓ platelet aggregation.",
    indications: [
      "Acute coronary syndrome",
      "Post-PCI (dual antiplatelet therapy with aspirin)",
    ],
    adverseEffects: [
      "Bleeding",
      "Dyspnea (common, usually benign)",
      "Bradycardia (transient)",
    ],
    boardsPearls: [
      "Reversible P2Y12 inhibitor — faster onset/offset than clopidogrel",
      "Active drug (not a prodrug) — no CYP2C19 dependence",
      "Twice-daily dosing; avoid >100 mg/day aspirin (↓ efficacy)",
    ],
  },
  {
    id: "prasugrel",
    name: "Prasugrel",
    aliases: ["prasugrel", "effient"],
    drugClass: "P2Y12 ADP receptor antagonist (thienopyridine)",
    mechanism:
      "Irreversible P2Y12 ADP receptor blockade → more potent and faster-acting than clopidogrel.",
    indications: [
      "Acute coronary syndrome undergoing PCI",
    ],
    adverseEffects: [
      "Bleeding (higher than clopidogrel)",
      "Thrombotic thrombocytopenic purpura (rare)",
    ],
    boardsPearls: [
      "More potent thienopyridine than clopidogrel — faster onset",
      "Contraindicated with prior stroke/TIA (↑ ICH risk)",
      "Contraindicated if age ≥75 or weight <60 kg (bleeding risk)",
    ],
  },
  {
    id: "eptifibatide",
    name: "Eptifibatide",
    aliases: ["eptifibatide", "integrilin"],
    drugClass: "Glycoprotein IIb/IIIa inhibitor",
    mechanism:
      "Blocks fibrinogen binding to GPIIb/IIIa receptor on activated platelets → inhibits final common pathway of platelet aggregation.",
    indications: [
      "High-risk ACS undergoing PCI",
      "PCI with glycoprotein IIb/IIIa inhibitor bailout",
    ],
    adverseEffects: [
      "Bleeding (major risk)",
      "Thrombocytopenia",
    ],
    boardsPearls: [
      "Blocks final common pathway of platelet aggregation (GPIIb/IIIa)",
      "IV use only — short half-life; used in cath lab setting",
      "Contraindicated with severe thrombocytopenia or active bleeding",
      "Abciximab and tirofiban are other GPIIb/IIIa inhibitors",
    ],
  },
  {
    id: "cilostazol",
    name: "Cilostazol",
    aliases: ["cilostazol", "pletal"],
    drugClass: "Phosphodiesterase-3 inhibitor / antiplatelet agent",
    mechanism:
      "Inhibits PDE-3 → ↑ cAMP in platelets and vascular smooth muscle → antiplatelet effect and vasodilation.",
    indications: [
      "Intermittent claudication (peripheral arterial disease)",
      "Secondary stroke prevention (selected patients)",
    ],
    adverseEffects: [
      "Headache, diarrhea, palpitations",
      "Contraindicated in heart failure (PDE-3 inhibitors ↑ mortality in HF)",
    ],
    boardsPearls: [
      "PDE-3 inhibitor — antiplatelet + vasodilator for claudication",
      "Contraindicated in heart failure (same class as milrinone — ↑ mortality)",
      "Improves walking distance in PAD; not first-line for ACS",
    ],
  },
  {
    id: "nsaid",
    name: "NSAID",
    aliases: [
      "nsaid",
      "nsaids",
      "nonsteroidal anti-inflammatory drug",
      "nonsteroidal anti-inflammatory drugs",
      "non-steroidal anti-inflammatory drug",
    ],
    drugClass: "Nonsteroidal anti-inflammatory drug (NSAID)",
    mechanism:
      "Inhibits cyclooxygenase (COX) → ↓ prostaglandin and thromboxane A₂ synthesis → analgesic, antipyretic, anti-inflammatory effects; COX-1 inhibition also ↓ platelet aggregation and protects gastric mucosa.",
    indications: [
      "Pain, fever, inflammation (arthritis, dysmenorrhea, headache)",
      "Aspirin at low dose used for antiplatelet effect (irreversible COX-1 inhibition)",
    ],
    adverseEffects: [
      "GI bleeding and peptic ulcer disease (↓ protective PGE₂)",
      "Renal insufficiency (afferent arteriole vasoconstriction when prostaglandins blunted)",
      "Hypertension, fluid retention",
      "Cardiovascular thrombotic risk with chronic use (except low-dose aspirin)",
    ],
    boardsPearls: [
      "COX-1: platelets, gastric mucosa; COX-2: inflamed tissue — selective COX-2 inhibitors ↓ GI ulcer risk but ↑ CV risk",
      "Aspirin irreversibly acetylates COX-1; other NSAIDs reversibly inhibit COX",
      "NSAIDs ↓ renal blood flow — avoid in CKD, heart failure, dehydration",
      "Combine with PPI if GI risk; avoid NSAIDs in active PUD",
    ],
  },
  {
    id: "naproxen",
    name: "Naproxen",
    aliases: ["naproxen", "aleve", "naprosyn"],
    drugClass: "NSAID",
    mechanism:
      "Reversibly inhibits COX-1 and COX-2 → ↓ prostaglandin synthesis → analgesic, antipyretic, anti-inflammatory effects; COX-1 inhibition also ↓ thromboxane A₂.",
    indications: [
      "Pain, fever, inflammation (arthritis, dysmenorrhea)",
      "Not used as primary antiplatelet agent",
    ],
    adverseEffects: [
      "GI bleeding and peptic ulcer disease",
      "Renal insufficiency (afferent arteriole vasoconstriction)",
      "Hypertension, fluid retention",
      "Cardiovascular risk with chronic use",
    ],
    boardsPearls: [
      "NSAID — reversible COX inhibition (unlike aspirin’s irreversible COX-1 blockade)",
      "↑ cardiovascular thrombotic risk with chronic NSAID use",
      "Avoid in CKD, heart failure, active GI bleeding",
      "Pediatrics: avoid in dehydration (renal toxicity); not for fever in viral illness if aspirin alternatives preferred",
    ],
  },
  {
    id: "aspirin",
    name: "Aspirin",
    aliases: ["aspirin", "asa", "acetylsalicylic acid"],
    drugClass: "NSAID / antiplatelet agent",
    mechanism:
      "Irreversibly inhibits cyclooxygenase (COX-1 >> COX-2) → ↓ thromboxane A₂ synthesis → inhibits platelet aggregation; at higher doses also ↓ prostaglandins → analgesic, antipyretic, anti-inflammatory effects.",
    indications: [
      "Acute coronary syndrome (antiplatelet)",
      "Secondary prevention of MI, stroke, and cardiovascular events",
      "Kawasaki disease (with IVIG)",
      "Analgesia, fever, inflammation (higher doses)",
    ],
    adverseEffects: [
      "GI bleeding and peptic ulcer disease",
      "Bleeding (prolonged platelet dysfunction ~7–10 days)",
      "Tinnitus and salicylate toxicity (high doses)",
      "Reye syndrome in children with viral illness",
      "Asthma exacerbation (aspirin-exacerbated respiratory disease)",
    ],
    boardsPearls: [
      "Irreversible COX-1 inhibition → antiplatelet effect lasts platelet lifespan (~7–10 days)",
      "Contraindicated in children with febrile viral illness (Reye syndrome)",
      "Low-dose: antiplatelet; high-dose: analgesic/antipyretic/anti-inflammatory",
      "Pediatrics: avoid for fever in varicella/influenza; used in Kawasaki disease",
    ],
  },
  {
    id: "metformin",
    name: "Metformin",
    aliases: ["metformin"],
    drugClass: "Biguanide",
    mechanism:
      "↓ hepatic gluconeogenesis and improves peripheral insulin sensitivity; does not stimulate insulin secretion.",
    indications: [
      "Type 2 diabetes mellitus",
      "PCOS",
      "Prediabetes",
    ],
    adverseEffects: [
      "GI upset (nausea, diarrhea)",
      "Lactic acidosis (rare, especially with renal failure)",
      "Vitamin B12 deficiency (chronic use)",
    ],
    boardsPearls: [
      "↓ hepatic gluconeogenesis; does not stimulate insulin secretion",
      "Contraindicated in eGFR <30 (lactic acidosis risk)",
      "Does not cause hypoglycemia as monotherapy",
    ],
  },
  {
    id: "insulin",
    name: "Insulin",
    aliases: ["insulin"],
    drugClass: "Hormone / hypoglycemic agent",
    mechanism:
      "Binds insulin receptor → promotes glucose uptake, glycogenesis, lipogenesis; inhibits gluconeogenesis and lipolysis.",
    indications: [
      "Type 1 diabetes mellitus",
      "Type 2 diabetes (when oral agents insufficient)",
      "Hyperkalemia (with glucose)",
      "Diabetic ketoacidosis / hyperosmolar hyperglycemic state",
    ],
    adverseEffects: [
      "Hypoglycemia (most serious)",
      "Weight gain",
      "Lipohypertrophy at injection sites",
      "Hypokalemia (insulin drives K⁺ intracellularly during DKA correction)",
    ],
    boardsPearls: [
      "Drives K⁺ intracellularly — given with glucose for hyperkalemia",
      "β-blockers mask hypoglycemia symptoms (tachycardia, tremor)",
      "Formulations differ by onset and duration (rapid, NPH, glargine, etc.)",
    ],
  },
  {
    id: "levothyroxine",
    name: "Levothyroxine",
    aliases: ["levothyroxine", "synthroid"],
    drugClass: "Synthetic T4 (thyroid hormone)",
    mechanism:
      "Peripheral conversion to T3 → binds nuclear receptors → regulates metabolic gene transcription.",
    indications: [
      "Hypothyroidism",
      "Thyroid cancer suppression therapy",
      "Myxedema coma",
    ],
    adverseEffects: [
      "Symptoms of hyperthyroidism if overdosed (palpitations, weight loss, heat intolerance)",
      "Atrial fibrillation in elderly if over-replaced",
    ],
    boardsPearls: [
      "T4 prodrug → peripheral conversion to active T3",
      "Many drug interactions (Ca²⁺, Fe, PPIs ↓ absorption)",
      "Pregnancy ↑ thyroid hormone requirements; TSH guides adequacy",
    ],
  },
  {
    id: "prednisone",
    name: "Prednisone",
    aliases: ["prednisone"],
    drugClass: "Glucocorticoid",
    mechanism:
      "Binds glucocorticoid receptor → alters gene transcription → anti-inflammatory, immunosuppressive, and metabolic effects.",
    indications: [
      "Autoimmune and inflammatory disorders",
      "Asthma/COPD exacerbations",
      "Adrenal insufficiency",
      "Transplant rejection",
      "Allergic reactions",
    ],
    adverseEffects: [
      "Cushingoid features, hyperglycemia, hypertension",
      "Osteoporosis, avascular necrosis",
      "Immunosuppression, poor wound healing",
      "Adrenal suppression with prolonged use",
    ],
    boardsPearls: [
      "Taper after chronic use to avoid adrenal crisis",
      "Worsens infections; can mask fever",
      "Hyperglycemia and psychosis are classic acute effects",
    ],
  },
  {
    id: "haloperidol",
    name: "Haloperidol",
    aliases: ["haloperidol", "haldol"],
    drugClass: "Typical (first-generation) antipsychotic",
    mechanism:
      "Dopamine D2 receptor antagonism in mesolimbic pathway → ↓ positive psychotic symptoms.",
    indications: [
      "Schizophrenia",
      "Acute agitation / psychosis",
      "Tourette syndrome",
      "Severe nausea/vomiting",
    ],
    adverseEffects: [
      "Extrapyramidal symptoms (dystonia, akathisia, parkinsonism, tardive dyskinesia)",
      "Hyperprolactinemia",
      "QT prolongation",
      "Neuroleptic malignant syndrome",
    ],
    boardsPearls: [
      "High-potency typical antipsychotic → more EPS, less sedation/anticholinergic effects",
      "NMS: rigidity, fever, autonomic instability, ↑ CK — dopamine blockade toxicity",
      "Avoid in Lewy body dementia (severe sensitivity)",
    ],
  },
  {
    id: "lorazepam",
    name: "Lorazepam",
    aliases: ["lorazepam", "ativan"],
    drugClass: "Benzodiazepine",
    mechanism:
      "Enhances GABA-A receptor activity → ↑ Cl⁻ influx → neuronal hyperpolarization and CNS depression.",
    indications: [
      "Anxiety",
      "Alcohol withdrawal",
      "Status epilepticus",
      "Preprocedure sedation",
    ],
    adverseEffects: [
      "Sedation, confusion (especially elderly)",
      "Respiratory depression (with opioids)",
      "Dependence and withdrawal",
      "Ataxia",
    ],
    boardsPearls: [
      "Alcohol withdrawal: GABA facilitation prevents seizures and delirium tremens",
      "Flumazenil reverses overdose but may precipitate seizures",
      "Avoid combining with alcohol/opioids",
    ],
  },
  {
    id: "fluoxetine",
    name: "Fluoxetine",
    aliases: ["fluoxetine", "prozac"],
    drugClass: "SSRI",
    mechanism:
      "Selectively inhibits presynaptic serotonin reuptake → ↑ synaptic 5-HT.",
    indications: [
      "Major depressive disorder",
      "OCD, panic disorder, bulimia nervosa",
      "PTSD",
    ],
    adverseEffects: [
      "GI upset, sexual dysfunction, insomnia",
      "Serotonin syndrome (with MAOIs, other serotonergic drugs)",
      "Bleeding risk (↓ platelet serotonin)",
      "Activation / increased suicidality in young adults (early treatment)",
    ],
    boardsPearls: [
      "Long half-life (active metabolite norfluoxetine)",
      "Do not combine with MAOIs",
      "Serotonin syndrome: hyperthermia, clonus, agitation, autonomic instability",
    ],
  },
  {
    id: "gentamicin",
    name: "Gentamicin",
    aliases: ["gentamicin"],
    drugClass: "Aminoglycoside antibiotic",
    mechanism:
      "Binds 30S ribosomal subunit → misreading of mRNA → bactericidal against aerobic Gram-negative rods.",
    indications: [
      "Serious Gram-negative infections (often combined with β-lactam)",
      "Endocarditis (synergy with cell-wall agents)",
      "Uncomplicated UTI (selected cases)",
    ],
    adverseEffects: [
      "Nephrotoxicity",
      "Ototoxicity (vestibular and cochlear)",
      "Neuromuscular blockade",
    ],
    boardsPearls: [
      "Binds 30S ribosomal subunit → misreading of mRNA (concentration-dependent killing)",
      "Synergistic with β-lactams for enterococcal endocarditis (cell-wall + protein synthesis)",
      "Nephrotoxic and ototoxic — risk ↑ with loop diuretics and vancomycin",
    ],
  },
  {
    id: "vancomycin",
    name: "Vancomycin",
    aliases: ["vancomycin"],
    drugClass: "Glycopeptide antibiotic",
    mechanism:
      "Inhibits cell wall peptidoglycan polymerization by binding D-Ala-D-Ala → bactericidal against Gram-positive cocci.",
    indications: [
      "MRSA infections",
      "Serious Gram-positive infections (endocarditis, meningitis)",
      "C. difficile colitis (oral formulation)",
    ],
    adverseEffects: [
      "Nephrotoxicity",
      "Red man syndrome (rapid infusion — histamine release)",
      "Ototoxicity",
      "Thrombophlebitis",
    ],
    boardsPearls: [
      "Binds D-Ala-D-Ala → inhibits peptidoglycan polymerization (Gram-positive)",
      "Red man syndrome from rapid infusion (histamine release, not true allergy)",
      "Oral vancomycin not absorbed — treats C. difficile in gut lumen only",
    ],
  },
  {
    id: "sildenafil",
    name: "Sildenafil",
    aliases: [
      "sildenafil",
      "viagra",
      "revatio",
      "phosphodiesterase type 5 inhibitor",
      "phosphodiesterase-5 inhibitor",
      "phosphodiesterase 5 inhibitor",
      "pde-5 inhibitor",
      "pde5 inhibitor",
    ],
    drugClass: "Phosphodiesterase type 5 (PDE-5) inhibitor",
    mechanism:
      "Inhibits PDE-5 → prevents cGMP degradation → ↑ cGMP in vascular smooth muscle → vasodilation (systemic and pulmonary).",
    indications: [
      "Erectile dysfunction",
      "Pulmonary arterial hypertension (PAH)",
    ],
    adverseEffects: [
      "Headache, flushing, dyspepsia",
      "Hypotension (especially with nitrates or α-blockers)",
      "Visual disturbances (blue tinge; PDE-6 cross-reactivity in retina)",
      "Priapism (rare)",
    ],
    boardsPearls: [
      "Absolute contraindication with nitrates (e.g., nitroglycerin) → life-threatening hypotension",
      "Also inhibits PDE-6 in retina → blue-tinged vision",
      "Metabolized by CYP3A4 — levels ↑ with ritonavir and grapefruit",
      "Same drug as Revatio; PAH dosing differs from erectile dysfunction dosing",
      "Pediatrics: approved for PAH in children ≥1 year (weight-based dosing)",
    ],
  },
  {
    id: "tmp-smx",
    name: "Trimethoprim-Sulfamethoxazole",
    aliases: [
      "trimethoprim-sulfamethoxazole",
      "tmp-smx",
      "tmp/smx",
      "bactrim",
      "septra",
    ],
    drugClass: "Sulfonamide + folate synthesis inhibitor",
    mechanism:
      "Sulfamethoxazole inhibits dihydropteroate synthase; trimethoprim inhibits dihydrofolate reductase → blocks bacterial folate synthesis.",
    indications: [
      "Uncomplicated UTI",
      "Pneumocystis jirovecii pneumonia (prophylaxis and treatment)",
      "MRSA skin infections (community)",
      "Toxoplasmosis prophylaxis",
    ],
    adverseEffects: [
      "Hyperkalemia (trimethoprim blocks ENaC)",
      "Stevens-Johnson syndrome / TEN",
      "Hemolytic anemia in G6PD deficiency",
      "Crystalluria, nephrotoxicity",
    ],
    boardsPearls: [
      "Avoid in third trimester and near term (kernicterus risk)",
      "Classic cause of hyperkalemia in elderly",
      "Increase warfarin effect",
    ],
  },
  {
    id: "tacrolimus",
    name: "Tacrolimus",
    aliases: ["tacrolimus", "fk506", "prograf", "advagraf", "astagraf"],
    drugClass: "Calcineurin inhibitor (immunosuppressant)",
    mechanism:
      "Binds FKBP-12 → inhibits calcineurin → blocks NFAT dephosphorylation → ↓ IL-2 transcription → ↓ T-cell activation and proliferation.",
    indications: [
      "Solid organ transplant rejection prophylaxis (kidney, liver, heart, lung)",
      "Topical formulation for atopic dermatitis (lower systemic exposure)",
      "Steroid-sparing immunosuppression in some autoimmune diseases",
    ],
    adverseEffects: [
      "Nephrotoxicity (vasoconstriction, acute and chronic kidney injury)",
      "Neurotoxicity (tremor, headache, posterior reversible encephalopathy syndrome)",
      "Hyperglycemia / new-onset diabetes after transplant",
      "Hypertension, hyperkalemia, hypomagnesemia",
      "Increased infection and malignancy risk (EBV → PTLD)",
    ],
    boardsPearls: [
      "Calcineurin inhibitor — same pathway as cyclosporine; tacrolimus more potent",
      "Monitor trough levels; nephrotoxicity is dose- and level-dependent",
      "CYP3A4 substrate — levels ↑ with azoles, macrolides, grapefruit; ↓ with rifampin",
      "vs cyclosporine — both inhibit calcineurin; tacrolimus more commonly used in modern transplant regimens",
      "Peds: used in pediatric transplant; growth and infection monitoring essential",
    ],
  },
];

const medicationById = new Map(MEDICATIONS.map((m) => [m.id, m]));

export function getMedicationById(id: string): MedicationEntry | undefined {
  return medicationById.get(id);
}

export interface MedicationAliasMatch {
  alias: string;
  medicationId: string;
}

export function buildMedicationAliasIndex(): MedicationAliasMatch[] {
  const matches: MedicationAliasMatch[] = [];
  for (const medication of MEDICATIONS) {
    for (const alias of medication.aliases) {
      matches.push({ alias: alias.toLowerCase(), medicationId: medication.id });
    }
  }
  return matches.sort((a, b) => b.alias.length - a.alias.length);
}
